Targeting the Oligomerization Domain of ETO Interferes With RUNX1/ETO Oncogenic Activity in T(8;21)-Positive Leukemic Cells

Cancer Research - United States
doi 10.1158/0008-5472.can-06-3360
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

NHR4 Domain Mutations of ETO Are Probably Very Infrequent in AML1–ETO Positive Myeloid Leukemia Cells

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

Detection of DNA Rearrangements in the AML1 and ETO Loci and of an AML1/ETO Fusion mRNA in Patients With T(8;21) Acute Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
1993English

MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML

Cell Reports
BiochemistryGeneticsMolecular Biology
2016English

RUNX1–ETO Upregulates CCND2 to Drive Leukemogenesis

Cancer Discovery
Oncology
2018English

The AML1/ETO Target Gene LAT2 Interferes With Differentiation of Normal Hematopoietic Precursor Cells

Leukemia Research
Cancer ResearchOncologyHematology
2014English

Oligomerization of ETO Is Obligatory for Corepressor Interaction

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2001English

Subcellular Localization of the Oncoprotein MTG8 (CDR/ETO) in Neural Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
1998English

ETO, but Not Leukemogenic Fusion Protein AML1/ETO, Augments RBP-J /SHARP-Mediated Repression of Notch Target Genes

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2008English

A Histone Acetyltransferase P300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy